ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX), a biopharmaceutical company focused on clinical development of antiviral and anticancer technologies, recently delivered a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo. ADVENTRX Pharmaceuticals’ president and chief executive officer, Evan M. Levine, spoke at the convention, noting that the company is working to improve the performance and commercial potential of its existing therapies.

Specifically targeting the oncology market, the company is currently focused on advancing its novel emulsion formulations of marketed chemotherapy drugs, ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion). ADVENTRX Pharmaceuticals plans to file NDAs for these therapies in 2009, which could potentially be on the market by 2010, representing a market opportunity of more than $3 billion.

ADVENTRX Pharmaceuticals is also developing ANX-510, a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce the associated toxicity of the widely used cancer chemotherapeutic agent. The global market for this therapy is in excess of $500 million.

Let us hear your thoughts below: